In addition, measurement of plasma resistin levels in combination with resistin mRNA and CAP-1 mRNA (adenylate cyclase-associated protein 1; resistin receptor) in peripheral blood mononuclear cells (PBMCs) has independently shown significant predictive value for CRC risk. This evidence concerns the gene CAP1 and colorectal carcinoma.